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Our study was aimed to assess the clinical correlates
of different degrees of renal dysfunction in a wide
group of non-diabetic hypertensive patients, free from
cardiovascular (CV) complications and known renal
diseases, participating to the REDHY (REnal Dysfunc-
tion in HYpertension) study. A total of 1856 hypertensive
subjects (mean age: 47±14 years), attending our hyper-
tension centre, were evaluated. The glomerular filtration
rate (GFR) was estimated by the simplified Modifica-
tion of Diet in Renal Disease Study prediction equation.
A 24-h urine sample was collected to determine albumin
excretion rate (AER). Albuminuria was defined as an
AER greater than 20lgmin
 1. We used the classifica-
tion proposed by the US National Kidney Foundation’s
guidelines for chronic kidney disease (CKD) to define
the stages of renal function impairment. In multiple
logistic regression analysis, the probability of having
stage 1 and stage 2 CKD was significantly higher in
subjects with greater values of systolic blood pressure
(SBP) and with larger waist circumference. SBP was
also positively related to stage 3 CKD. Stage 3 and
stages 4–5 CKD were inversely associated with waist
circumference and directly associated with serum uric
acid. Age was inversely related to stage 1 CKD and
directly related to stage 3 CKD. The factors associated
with milder forms of kidney dysfunction are, in part,
different from those associated with more advanced
stages of renal function impairment.
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doi:10.1038/jhh.2009.41; published online 14 May 2009
Keywords: arterial hypertension; renal dysfunction; albuminuria; estimated glomerular filtration rate
Introduction
Recent guidelines for the management of hyperten-
sion have recognized the relevance of albuminuria
and an estimated glomerular filtration rate (eGFR)
value o60mlmin
 1 per 1.73m
2 on cardiovascular
(CV) prognosis of hypertensive patients.
1–3 The
presence or absence of albumin in urine and the
level of eGFR allow patients to be allocated to one of
the five stages of chronic kidney disease (CKD),
described by the US National Kidney Foundation’s
(NKF) Kidney Disease Outcomes Quality Initiative
(K/DOQI) guidelines,
4 which is the accepted classi-
fication of any renal disease.
The available information about the prevalence
of renal dysfunction in arterial hypertension arises
chiefly from clinical trials enrolling elderly hyper-
tensive subjects or patients with high or very high
CV risk.
5–8 Little is known about the clinical corre-
lates of the various stages of kidney disease in
arterial hypertension, especially in patients without
diabetes and free from CV complications.
We recently found that renal dysfunction is highly
prevalent among non-diabetic middle-aged subjects
with non-malignant arterial hypertension and with-
out CV complications, participating to the REDHY
(REnal Dysfunction in HYpertension) study.
9
The aim of this study was to analyse, in the same
wide group of hypertensive subjects, the clinical
correlates of different degrees of renal dysfunction.
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The study population was selected from 2258
Caucasian hypertensive patients consecutively
attending our hypertension centre. Most of them
had been referred to our institution by their general
practitioners for specialist advice.
Exclusion criteria:
  Age lower than 18 years and greater than 70 years
  Known diabetes or fasting glycaemiaX126mg per
100ml
  Grade II–III (World Health Organization classifica-
tion) obesity (body mass index (BMI)435kg/m
2)
  Known renal, renovascular, malignant or endo-
crine hypertension
  Known proteinuria and haematuria
  Previous known nephritic diseases and hereditary
renal diseases
  Heart failure
  Positive history or clinical signs of ischaemic
heart disease
  Positive history or clinical signs of cerebrovas-
cular diseases
  Major non-cardiovascular diseases
  Unreliable 24-h urine collection. (that is, cre-
atinine excretion o10mgkg
 1 for women and
o15mgkg
 1 for men was considered undercollec-
tion; a urinary creatinine ouptut430mgkg
 1 in
men and425mgkg
 1 in women was considered
as overcollection).
10
Endocrine and renovascular hypertension was
ruled out by clinical examination, and determina-
tion of serum electrolytes, plasma renin activity,
plasma aldosterone, plasma catecholamines and
where appropriate, by performing renal echography,
echo-doppler of renal arteries and renoscintigraphy.
Written informed consent was obtained from each
subject and the study was approved by the local
review board.
In all subjects, careful clinical history and
physical examination were performed. Body weight,
height and waist circumference were measured by
a nurse and clinic blood pressure was recorded by
a doctor, following the recommendations of the
2007 European Society of Hypertension/ European
Society of Cardiology guidelines.
1 Clinic blood
pressure was considered as the mean of three
consecutive measurements obtained by a mercury
sphygmomanometer, after 5min of rest in sitting
position. Blood samples were drawn to perform
routine blood chemistry.
Measurements
Serum and urine creatinine concentrations were
determined by the kinetic picrate method using an
autoanalyser (Monarch 2000 autoanalyser; Instru-
mentation Laboratories, Lexington, MA, USA). The
same analyser was used to determine the other
routine biochemical parameters. The 24-h albumin
excretion rate (AER) was assayed by radioimmuno-
logical analysis (Techno Genetics RIA Kit). In
subjects with urinary tract infections, AER was
determined only after appropriate antibacterial
treatment. Urine collections were carried out on
non-working days. The patients were advised to
avoid excessive physical efforts on the day before
and during the 24-h urine collections. Collections
were postponed in female participants reporting
menstruation or febrile illnesses at the time of
collection.
The GFR was estimated (eGFR) by the abbreviated
prediction equation of the Modification Diet in
Renal Disease Study (MDRD):
11
186 Serum creatinine (mg per 100ml)
–1.154 Age
(years)
–0.203 ( 0.742 for Women).
The ethnicity factor of the equation was not
used because our study population was exclusively
white.
Albuminuria was considered as 24-h AER4
20mgmin
 1. Microalbuminuria and macroalbumi-
nuria were defined as 24-h AER 20–199mgmin
 1
and X200mgmin
 1, respectively.
We used the classification proposed by the US
NKF K/DOQI guidelines for CKD to define the stages
of renal function impairment.
4 CKD stages were
defined as follows: stage 1, eGFR greater than
90mlmin
 1 per 1.73m
2 and 24-h AER420mgmin
 1;
stage 2, eGFR of 60 to 89mlmin
 1 per 1.73m
2 and
24-h AER420mgmin
 1; stage 3, eGFR of 30 to
59ml
 1min
 1 per 1.73m
2; stage 4, eGFR of 15 to
29mlmin
 1 per 1.73m
2; stage 5, eGFR less than
15mlmin
 1 per 1.73m
2.
4
Statistics
A total of 402 subjects met the exclusion criteria.
Therefore, the final analysis involved 1856 patients.
Continuous variables were given as mean±s.d.,
except for AER, which, because of its skewed dis-
tribution, was expressed as the median and inter-
quartile range. It was therefore log-transformed
before starting the statistical tests.
We used one-way ANOVA for independent sam-
ples to evaluate differences in means. Comparisons
of each stage of CKD with the group of subjects
without CKD were performed, if the overall F-test
was significant, by using the Holm post hoc test.
Proportional differences between groups were
assessed by the w
2-test, with Yates’ correction.
The relationship between eGFR and AER was
tested by the Pearson’s correlation coefficients.
To investigate the independent correlates of each
stage of CKD, multiple logistic regression analyses
were performed by calculating odd ratios and their
95% confidence limits, after adjustment for age,
systolic (SBP) and diastolic (DBP) blood pressures,
waist circumference, serum uric acid (SUA), trigly-
cerides, high-density lipoprotein (HDL) cholesterol,
total cholesterol, duration of hypertension (included
as continuous variables), gender, previous treatment
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Journal of Human Hypertensionfor hypertension, smoking habit (included as cate-
gorical variables). For this analysis, patients of stage
4 and stage 5 were pooled in a single group because
the low number of subjects belonging to the stage 5.
In all multiple regression analyses, a backward
stepwise procedure was used, with a¼0.15 as the
cut-off for entry or removal of variables, which is
the default value of the SYSTAT statistical package.
The null hypothesis was rejected at a two-tailed
Pp0.05.
The statistical analyses were performed using
the SYSTAT DATA software package, version 5.2
(Systat, Evanston, IL, USA).
Results
The mean age of the 1856 patients enrolled in the
study was 47±14 years, 53% of whom were men.
The median value and interquartile range of AER
were 9 (5–18.5) mgmin
 1. Microalbuminuria and
macroalbuminuria were detected, respectively, in
22.7 and 0.7% of the entire population. The mean
values of serum creatinine and estimated GFR were,
respectively, 0.97±0.58mg per 100ml and 89.7±
26mlmin
 1 per 1.73m
2. Only 5.2% of the overall
population had simultaneously albuminuria and an
estimated GFR less than 60mlmin
 1 per 1.73m
2.
AER and eGFR were weakly (r¼ 0.13), but signif-
icantly (Po0.001) inversely related.
The prevalence of the five stages of renal dys-
function is shown in Figure 1. The main clinical
characteristics of the hypertensive patients with the
different stages of CKD, compared to those without
CKD, are given in Table 1.
Of the patients enrolled in the study, 70% were
already pharmacologically treated for hypertension.
The antihypertensive treatment of this subgroup
was based on: ACE inhibitors (alone and in
combination with a diuretic; 35%); AT1 blockers
(alone and in combination with a diuretic; 25%),
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
024 8 61 0 1 2
%
0.2 %
2.3 %
7.5 %
9.6 %
8.8 %
Figure 1 Distribution of the stages of renal dysfunction (NKF
classification of chronic kidney disease (CKD)) in the study
population.
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Journal of Human Hypertensionb-blockers or a-b-blockers (alone and in combina-
tion with a diuretic; 11%), a-blockers (3%), calcium
antagonists (12%), a combination of two or more
of these drugs (14%). The distribution of the
antihypertensive therapy and of the classes of
BP-lowering drugs among the patients divided
according to the level of renal function is reported
in Table 2. Even if the prevalence of patients treated
for hypertension was higher in the group of subjects
belonging to stage 1 and stage 2 CKD, when com-
pared to the group without kidney dysfunction, the
percentage of subjects treated with ACE inhibitors
or AT1-blockers or other classes of antihypertensive
drugs did not differ significantly in the various
groups.
A stepwise multiple logistic regression model
(Table 3) in which each stage of CKD was considered
as outcome variable and including as covariates
age, SBP and DBP, waist circumference, SUA, tri-
glycerides, HDL cholesterol, total cholesterol, dura-
tion of hypertension, gender, previous treatment for
hypertension, smoking habit, revealed that SBP was
independently associated with stage 1, stage 2 and
stage 3 CKD, whereas waist circumference was
positively related to stage 1 and stage 2 CKD and
inversely associated with stage 3 and stages 4–5
CKD. The same analysis showed that SUA was an
independent predictor of stage 3 and stages 4–5 CKD
and age was negatively associated with stage 1 and
positively related to stage 3 CKD. Previous pharma-
cological antihypertensive therapy was positively
related to stage 1 and stage 2 CKD but these
associations attain statistical significance only for
stage 2 CKD (Table 3).
Discussion
This study showed that, in a population of non-
diabetic hypertensive subjects without CV compli-
cations, the factors associated with milder forms of
renal dysfunction are, in part, different from those
associated with more advanced stages of kidney
dysfunction.
Indeed, multiple logistic regression analysis dis-
closed that waist circumference, SBP and previous
pharmacological therapy for hypertension were
independent correlates of both stage 1 and stage 2
CKD, even if this latter association reached statis-
tical significance only for stage 2 CKD. These
findings are consistent with several previous studies
showing that SBP and abdominal obesity are two
important determinants of microalbuminuria,
12–16 a
key component of the two first stages of the NKF
classification of CKD.
The greater proportion of subjects, pharmaco-
logically treated for high BP, we found in the group
with stage 1 and stage 2 CKD when compared to the
group without renal dysfunction is probably due to
the longer duration of hypertension, the higher BP
values and the greater BMI observed in the former
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Journal of Human Hypertensionin comparison to the latter. It is likely that all these
characteristics prompted the general practitioners
to treat these patients with antihypertensive drugs
more frequently than those without CKD.
The inverse association we found between age
and stage 1 is likely attributable to the inclusion in
this stage of subjects with normal estimated GFR,
which is inversely related to age in the equation
used to calculate it by the MDRD study formula.
11
Probably for the opposite reason we found a direct
association between age and stage 3 CKD. This stage
was also independently related to increased SUA
and higher SBP values. Although SUA elevations
have long been recognized as marker of renal dis-
ease, they are not usually considered to have a
causal role in kidney dysfunction.
17 However, recent
epidemiologic studies have identified SUA eleva-
tions as an independent risk factor for CKD.
17,18 On
the other hand, it well known that the kidney may
be both a cause and a victim of high BP and there
is now a consensus that systolic, rather than dias-
tolic, BP poses the greater risk for renal function
deterioration.
19
Besides these expected relationships of stage 3
with SUA and SBP elevations, we observed an
inverse association between waist circumference
and stage 3 and stage 4–5 CKD. This finding seems
to be in contrast with recent evidence that high-
lighted the importance of obesity as risk factor
for end-stage renal disease.
20–21 However, it is
noteworthy that this evidence arises chiefly from
longitudinal studies performed in the general
population,
20–21 also including severely obese sub-
jects. In our study, patients with BMI greater than
35kg/m
2 were excluded to reduce the potential
influence on the prevalence of kidney dysfunction
of our population of the glomerulopathy related to
an increased BMI and especially to severe degrees
of obesity. Moreover, in some studies, conducted in
hypertensive persons, lower levels of BMI were
detected in subjects with decreased values of GFR,
such as in our study
6,8,22 and more recently the
Framingham Offspring Study showed that obesity
was not associated per se with an independent risk
to develop stage 3 CKD, after adjustment for known
CV disease risk factors.
23 Observational investiga-
tions suggested that nutritional status deteriorates
as GFR declines.
24,25 Therefore, undernutrition may
contribute to explain the negative relationship we
found between obesity and advanced stages of
CKD. However, the cross-sectional design of this
study does not allow us to establish the direction
of causality relations between obesity and renal
insufficiency. Some other aspects of our study need
to be discussed.
Increased AER and reduced eGFR were only
weakly related to each other (r¼0.13). This implies
that these two markers of renal dysfunction iden-
tify, in part, different groups of patients in the
hypertensive population. In fact, only 5.2% of
patients had simultaneously albuminuria and a
reduced eGFR. Moreover, the factors associated
with stages 1–2 CKD were at least, in part, distinct
from those related to stages 3–5 CKD. This obser-
vation suggests that milder forms of renal dys-
function and more advanced stages of kidney
dysfunction have partially different pathogenetic
mechanisms and may provide complementary infor-
Table 3 Independent predictors of stage 1, stage 2, stage 3 and stages 4–5 CKD in the overall study population
Variable Estimate (s.e.) Odds ratio 95% Confidence Interval P
Lower Upper
Stage 1
Age  0.05 (0.014) 0.951 0.926 0.977 o0.001
Systolic blood pressure 0.016 (0.004) 1.014 1.003 1.025 0.009
Waist circumference 0.025 (0.012) 1.026 1.004 1.050 0.026
Pharmacological treatment for hypertension 0.78 (0.434) 2.18 0.932 5.102 0.072
Stage 2
Systolic blood pressure 0.02 (0.006) 1.020 1.007 1.033 0.002
Waist circumference 0.032 (0.013) 1.029 1.009 1.052 0.004
Pharmacological treatment for hypertension 0.644 (0.281) 1.888 1.061 3.390 0.037
Stage 3
Age 0.086 (0.017) 1.090 1.053 1.128 o0.001
Serum uric acid 0.538 (0.119) 1.713 1.358 2.162 o0.001
Waist circumference  0.055 (0.021) 0.947 0.908 0.987 0.01
Systolic blood pressure 0.02 (0.009) 1.021 1.004 1.038 0.018
Stages 4–5
Serum uric acid 1.026 (0.207) 2.79 1.859 4.188 o0.001
Waist circumference  0.115 (0.043) 0.891 0.820 0.969 0.007
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Journal of Human Hypertensionmation regarding CVrisk. Our findings are, in part, in
line with recent observations obtained in hyperten-
sive individuals
26,27 and in general population.
28–30
All these data support recent recommendations
defining CKD
4 and stratifying subsequent risks based
on both decreased GFR and albuminuria.
1–3
To estimate the GFR we used the four-variable
formula proposed by the MDRD study, a method that
is now considered the best predictor of true GFR in
clinical settings
4,31,32 and a reliable tool for deter-
mining impaired kidney function in several popula-
tions.
3,32 This formula has been recently questioned,
because it may underestimate the true GFR in the
normal-high range.
31 Consequently, the MDRD equa-
tion should be used with caution in patients with
GFR460mlmin
 1 per 1.73m
2. Despite this limita-
tion, it has been clearly documented that the GFR
estimated by the MDRD formula is a powerful
prognosticator for adverse CV outcomes.
6,8,20,28–30,33
Moreover, in the hypertensive population of the
VALUE trial, the MDRD study equation was a better
predictor of CV events than the creatinine clearance
rate calculated by the Cockcroft–Gault formula.
8
Study limitations
Our study should be interpreted within the context
of its limitations.
The main limitation is the cross-sectional nature
of our investigation that precluded assessment of the
temporality of the observed associations and thus
determination of causality.
Another possible weakness in our results could
be represented by the influence of pharmacologic
treatment, even if it was taken into account in the
multivariate analyses. Moreover, the percentage of
subjects treated with ACE inhibitors or AT1-blockers
or other classes of antihypertensive drugs did not
differ significantly in the various groups.
It is well known that there is a considerable
intrapersonal variation of urinary albumin excre-
tion.
4,13 Therefore, the measurement of only one
value of AER may be another limitation of our
study. However, as reported in the methods section,
we adopted several precautions to reduce the
variability of AER. We previously performed a
study in 70 never-treated hypertensive subjects,
which underwent two measurements of the 24-h
AER at 1 week interval, using the same precautions
employed in this study.
34 We found a Spearman’s
correlation coefficient for these two measurements
of 0.75 (Po0.0001). Of those participants with
microalbuminuria at the fist examination, 81%
had microalbuminuria at the second evaluation.
34
Moreover, it is important to note that in several
studies, in which a relationship between AER and
CV prognosis was found, only one measurement
was performed.
13
In conclusion, in non-diabetic hypertensive patients
without CV complications the factors associated with
milder forms of renal dysfunction are, in part, different
from those associated with more advanced stages of
kidney dysfunction. This may suggest partially dis-
tinct pathogenetic mechanisms.
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